A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial Hypercholesterolaemia STrategy).

[1]  W. März,et al.  Systematic review of published Phase 3 data on anti‐PCSK9 monoclonal antibodies in patients with hypercholesterolaemia , 2016, British journal of clinical pharmacology.

[2]  A. Hoes,et al.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention , 2016, Atherosclerosis.

[3]  D. Rader,et al.  Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher , 2016, Cardiovascular Drugs and Therapy.

[4]  J. Danesh,et al.  Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. , 2016, Journal of the American College of Cardiology.

[5]  F. Kronenberg,et al.  Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Med , 2016, Clinical chemistry.

[6]  O. Descamps,et al.  Homozygous familial hypercholesterolemia in childhood: Genotype-phenotype description, established therapies and perspectives. , 2016, Atherosclerosis.

[7]  J. Car,et al.  Familial hypercholesterolaemia: a global call to arms , 2015 .

[8]  M. Krempf,et al.  ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia , 2015, European heart journal.

[9]  Dirk De Bacquer,et al.  Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. , 2015, Atherosclerosis.

[10]  J. Borén,et al.  Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment , 2015, European heart journal.

[11]  I. Mcdowell,et al.  Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales. , 2015, Atherosclerosis.

[12]  Lesley Burgess,et al.  PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[13]  A. Tonkin.  Faculty Opinions recommendation of Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. , 2014 .

[14]  S. Humphries,et al.  Clinical utility gene card for: Hyperlipoproteinemia, TYPE II , 2013, European Journal of Human Genetics.

[15]  Catherine Boileau,et al.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease , 2013, European heart journal.

[16]  Jennifer G. Robinson,et al.  Management of Familial Hypercholesterolemia: A Review of the Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia , 2013, Journal of managed care pharmacy : JMCP.

[17]  S. Yamashita,et al.  Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan. , 2012, Journal of atherosclerosis and thrombosis.

[18]  C. de Beaufort,et al.  Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. , 2011, Atherosclerosis.

[19]  S. Humphries,et al.  Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing , 2008, Clinical chemistry and laboratory medicine.

[20]  Pascal Verdonck,et al.  Rationale, design, methods and baseline characteristics of the Asklepios Study , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[21]  J. Kastelein,et al.  Silent ischaemia in familial hypercholesterolemia. , 2003, Atherosclerosis. Supplements.

[22]  O. Descamps,et al.  Impact of genetic defects on coronary atherosclerosis in patients suspected of having familial hypercholesterolaemia , 2003, European journal of clinical investigation.

[23]  L. V. Van Gaal,et al.  Low-density lipoprotein receptor gene mutation analysis and clinical correlation in Belgian hypercholesterolaemics. , 2001, Molecular and cellular probes.

[24]  F. van Leuven,et al.  Impact of genetic defects on atherosclerosis in patients suspected of familial hypercholesterolaemia , 2001, European journal of clinical investigation.

[25]  T. Sacchi,et al.  Effect of acute myocardial infarction on cholesterol ratios. , 2001, Chest.

[26]  F. van Leuven,et al.  The use of Achilles tendon ultrasonography for the diagnosis of familial hypercholesterolemia. , 2001, Atherosclerosis.

[27]  M. Leppert,et al.  Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. , 1993, The American journal of cardiology.

[28]  R. Scragg,et al.  Changes in serum lipid concentrations during first 24 hours after myocardial infarction. , 1987, British medical journal.

[29]  M. Taskinen,et al.  [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.